Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) Preferred Dividend Payments (2024 - 2025)

Caris Life Sciences has reported Preferred Dividend Payments over the past 2 years, most recently at -$299.0 million for Q4 2025.

  • Quarterly results put Preferred Dividend Payments at -$299.0 million for Q4 2025, down 410.28% from a year ago — trailing twelve months through Dec 2025 was $181.8 million (changed N/A YoY), and the annual figure for FY2025 was $85.4 million, down 11.35%.
  • Preferred Dividend Payments for Q4 2025 was -$299.0 million at Caris Life Sciences, down from $384.4 million in the prior quarter.
  • Over the last five years, Preferred Dividend Payments for CAI hit a ceiling of $384.4 million in Q2 2025 and a floor of -$299.0 million in Q4 2025.